Lymphoma section

Featured Lymphoma Content

Recent Advances in Management of Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma

Oncologist Michelle Fanale, MD, and oncology nurse Rinata Simien, RN, NP-C, discuss the clinical treatment options for patients with relapsed Hodgkin lymphoma and anaplastic large cell lymphoma.

Lymphoma News and Features

FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma

FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma

Mogamulizumab-kpkc (Poteligeo), a humanized monoclonal antibody that targets CCR4, provides a new treatment option for patients with MF and is the first FDA-approved therapy for SS.

Fertility Preservation in Hodgkin's Lymphoma Patients That Undergo Targeted Molecular Therapies: An Important Step Forward From the Chemotherapy Era

Fertility Preservation in Hodgkin's Lymphoma Patients That Undergo Targeted Molecular Therapies: An Important Step Forward From the Chemotherapy Era

[Cancer Management and Research] A review of fertility complications induced by chemotherapy and radiotherapy, as well as possible treatment options for HL patients with fertility problems.

Certain Risk Factors May Decrease Overall Survival in Pediatric B-NHL

Certain Risk Factors May Decrease Overall Survival in Pediatric B-NHL

A new analysis of FAB/LMB 96 looked into factors associated with shortened OS among children and adolescents with B-NHL.

Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma

Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma

Although involved-field radiotherapy (IFRT) has a high level of disease control in patients with follicular lymphoma, relapse frequently occurs; therefore, researchers sought to determine if adding chemotherapy would improve progression-free survival.

R-THP-COP a New Therapeutic Alternative for Diffuse Large B Cell Lymphoma

R-THP-COP a New Therapeutic Alternative for Diffuse Large B Cell Lymphoma

Results of a prospective phase 3 study demonstrated noninferiority of R-THP-COP for diffuse large B cell lymphoma to the standard of care, suggesting the regimen may be an alternative option for these patients.

Dual Inhibitor for Treating CLL/SLL, Follicular Lymphoma Granted Priority Review

Dual Inhibitor for Treating CLL/SLL, Follicular Lymphoma Granted Priority Review

Duvelisib, a first-in-class dual inhibitor of PI3K-delta and -gamma, was evaluated in patients with relapsed/refractory CLL/SLL and in patients with refractory indolent non-Hodgkin lymphoma.

PET Use May Allow Early Treatment Adjustment in Non-Hodgkin Lymphoma

PET Use May Allow Early Treatment Adjustment in Non-Hodgkin Lymphoma

The ability to make early adjustments to treatment has the potential to improve survival.

Nurse-led Interventions Improve Quality of Life for Lymphoma Survivors

Nurse-led Interventions Improve Quality of Life for Lymphoma Survivors

Patients with lymphoma were interviewed to determine their evaluation of a program that offered continuing clinical care with a nurse-led intervention in the early months of survivorship.

Management of Relapsed/Refractory Marginal Zone Lymphoma: Focus on Ibrutinib

Management of Relapsed/Refractory Marginal Zone Lymphoma: Focus on Ibrutinib

[Cancer Management and Research] A review of marginal zone lymphomas, a common and varied group of hematologic malignancies, and their treatment, with a focus on the Bruton's tyrosine kinase ibrutinib.

Long-term Survival Improving Over Time in Advanced Hodgkin Lymphoma

Long-term Survival Improving Over Time in Advanced Hodgkin Lymphoma

A review of SEER data revealed trends in incidence of advanced Hodgkin lymphoma, discrepancies among subgroups, and survival over 3 decades.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs